Limited data from pre-clinical (cell and animal) studies consistently demonstrated that GLP-1 agonists have a chondroprotective and immunomodulatory effect in osteoarthritis, with a dose-dependent effect, where its beneficial effects was found to be primarily mediated by inhibition of NF-κB activation. This evidence concerns the gene NFKB1 and osteoarthritis.